RaiseTrack

ArkeaBio

Boston-based startup developing a vaccine that reduces the methane cattle emit, with New Zealand dairy as its first market.

Industry
agtech, animal health
Location
Boston, MA

About

ArkeaBio is developing a vaccine to cut the methane that cattle belch. AgFunderNews reports that its first product targets a 10 to 15 percent methane reduction with dosing every three months for dairy cattle, that it is focusing on New Zealand first with first revenues planned for 2028, and that it cut its headcount by about a third. Frank Wooten is CEO. The SEC Form D lists the company as Arkea Bio Corp. at a Charlestown, MA address; the press calls it Boston-based.

Funding history

RoundDateAmountLead
Series A-2 20262026-09-29$15MAgriZeroNZ

Investors

  • AgriZeroNZ lead
  • Breakthrough Energy Ventures participant

Sources

Last verified:

  1. https://agfundernews.com/exclusive-arkeabio-raises-15m-for-livestock-methane-tech-cuts-headcount
    Type: reputable publication. Accessed 2026-10-12.
    AgFunderNews article dated 2026-09-30 (08:00 UTC). Reports that ArkeaBio, a Boston-based startup developing a vaccine to cut livestock methane, raised a $15 million Series A2 round led by AgriZeroNZ and supported by Breakthrough Energy, and cut its headcount by about a third. Names CEO Frank Wooten.
  2. https://agribusinesswire.com/articles/arkeabio-raises-15m-for-methane-vaccine-cuts-a-third-of-staff-13253390
    Type: reputable publication. Accessed 2026-10-12.
    Agribusiness Wire article dated 2026-09-29 (20:50 UTC). Reports the $15 million Series A2 led by AgriZeroNZ with support from Breakthrough Energy Ventures.
  3. https://agronewstoday.com/article/arkeabio-raises-15m-livestock-methane-vaccine
    Type: reputable publication. Accessed 2026-10-12.
    Agro News Today article dated 2026-09-30, crediting AgFunderNews. Reports the $15 million Series A2 led by AgriZeroNZ with support from Breakthrough Energy.
  4. https://www.sec.gov/Archives/edgar/data/2004801/000200480126000001/0002004801-26-000001-index.htm
    Type: sec filing. Accessed 2026-10-12.
    SEC Form D for Arkea Bio Corp., Charlestown, MA, signed 2026-10-09. Reports $14,999,995 of equity sold out of $32,999,992 offered to 2 investors, first sale 2026-09-28. It does not name investors or a round type.